淋巴浆细胞性/淋巴浆细胞样淋巴瘤：一种与慢性淋巴细胞白血病不同的临床实体？

Lymphoplasmacytic/lymphoplasmacytoid lymphoma: a clinical entity distinct from chronic lymphocytic leukaemia?

作者信息

Heinz R, Stacher A, Pralle H, Theml H, Brunswicker F, Burkert M, Common H, Fülle H H, Grisar T, Grüneisen A, Herrmann F, Leopold H, Liffers R, Meusers P, Nowicki L, Nürnberger R, Rengshausen H, Rühl U, Schoengen A, Schmidt M, Wirthmüller R, Schwarze E W, Brittinger G

出版信息

Blut. 1981 Sep;43(3):183-92. doi: 10.1007/BF00363888.

DOI:10.1007/BF00363888

PMID:7343014

Abstract

Clinical data of 116 patients with chronic lymphocytic leukaemia (CLL) and of 114 patients with lymphoplasmacytic/lymphoplasmacytoid lymphoma (synonym: LP immunocytoma, IC) as diagnosed according to the Kiel classification were compared. This interim evaluation of a prospective multicenter study of the Kiel Lymphoma Study Group characterizes IC the less favorable lymphoma entity as evidenced by a more rapid lymph node enlargement, by a higher incidence of constitutional symptoms and of marked anaemia, and by a higher percentage of patients requiring early treatment. In addition, in IC autoimmune haemolytic anaemia was detected in 11.2% of investigated patients as compared to none of the patients with CLL, and monoclonal gammopathy was disclosed in 34.2% of investigated patients as compared to only three patients with CLL who could be, however, unrecognized cases of IC. Actuarial survival data after a follow-up period of 40 months are in favor of an overall better prognosis of patients with CLL than of patients with IC.

摘要

对116例慢性淋巴细胞白血病（CLL）患者和114例根据基尔分类法诊断为淋巴浆细胞性/淋巴浆细胞样淋巴瘤（同义词：LP免疫细胞瘤，IC）的患者的临床数据进行了比较。基尔淋巴瘤研究组一项前瞻性多中心研究的这项中期评估表明，IC是预后较差的淋巴瘤类型，表现为淋巴结肿大更快、全身症状和明显贫血的发生率更高，以及需要早期治疗的患者比例更高。此外，在IC患者中，11.2%的受调查患者检测出自身免疫性溶血性贫血，而CLL患者中无一例出现；34.2%的受调查IC患者发现单克隆丙种球蛋白病，而CLL患者中只有3例可能是未被识别的IC病例。随访40个月后的精算生存数据表明，CLL患者的总体预后优于IC患者。